Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial

NCT02244125 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT02244125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02244125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
Lead sponsor
Institut Curie
Phase
Phase 2
Overall status
Completed
Start date
April 14, 2014
Completion date
May 29, 2023
Enrollment
100 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

first relapse, multiple myeloma